<![CDATA[177Lu-Dotatate Combo Shows Consistent Efficacy Across GEP-NET Subgroups]]>

Data Readoutpositivelutetium Lu 177 dotatatePositive

AI Analysis

Summary

NETTER-2 trial results demonstrated consistent efficacy of first-line lutetium Lu 177 dotatate in reducing progression or death risk across advanced GEP-NET patient subgroups.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

NETTER-2 findings showed consistent reduction in risk of progression or death with first-line lutetium Lu 177 dotatate across advanced GEP-NET subgroups

Importance:6/10

Sentiment:

0.70

oncologyneuroendocrine tumorsGEP-NETclinical trialNETTER-2

Related Companies

$TRAX

Read the original article

Published by Cancer Network on August 14, 2026 3:00 PM

Read Original